| Literature DB >> 36230431 |
Yohannes E Messele1, Mauida F Hasoon2, Darren J Trott2, Tania Veltman2, Joe P McMeniman3, Stephen P Kidd2,4, Wai Y Low1, Kiro R Petrovski1,2.
Abstract
Enterococcus faecium are commensal bacteria inhabiting the gastrointestinal tract of animals and humans and an important cause of drug-resistant nosocomial infections. This longitudinal study aimed to determine whether changes in the antimicrobial resistance (AMR) phenotype and genotype occurred among Enterococcus spp. isolated from cattle rectal samples obtained at the entry to and exit from an Australian feedlot. The samples obtained at the feedlot induction yielded enterococci (104/150; 69.3%), speciated as E. hirae (90/104; 86.5%), E. faecium (9/104; 8.7%), E. mundtii (3/104; 2.9%), E. durans, and E. casseliflavus (1/104; 1.0% each). AMR was observed to lincomycin (63/104; 60.6%), daptomycin (26/104; 25.0%), nitrofurantoin (9/104; 8.7%), ciprofloxacin (7/104; 6.7%), tetracycline (5/104; 4.8%), tigecycline (4/104; 3.9%), and quinupristin/dalfopristin (3/104; 2.9%). From the rectal swab samples collected at the abattoir from the same animals (i.e., the feedlot exit), the enterococci recovery was significantly higher (144/150; 96.0%), with a marked shift in species distribution dominated by E. faecium (117/144; 81.3%). However, the prevalence of AMR to individual antimicrobials remained largely static between the entry and exit except for the increased resistance to nitrofurantoin (77/144; 53.5%) and quinupristin/dalfopristin (26/144; 18.1%). Overall, 13 AMR genes were observed among the 62 E. faecium isolates. These included aac(6')Ii, aac(6')-Iid, and ant(6)-Ia (aminoglycosides); eatAv, lnu(G), vat(E), msr(C), and erm(B) (macrolides, lincosamides, and streptogramins); efmA (fluoroquinolones); and tet(45), tet(L), tet(M), and tet(S) (tetracyclines). The results confirm the presence of fluoroquinolone- and streptogramin-resistant enterococci in cattle faeces at the feedlot entry in the absence of antimicrobial selection pressure. E. faecium, exhibiting increased nitrofurantoin resistance, became the dominant Enterococcus spp. during the feeding period.Entities:
Keywords: cattle; microbiology; multidrug resistance; surveillance
Year: 2022 PMID: 36230431 PMCID: PMC9559632 DOI: 10.3390/ani12192690
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Dilution ranges and breakpoints used for antimicrobial susceptibility testing of Enterococcus isolates of faecal origin.
| Antimicrobial Agent | Range | Breakpoints for Resistance |
|---|---|---|
| Chloramphenicol | 2–32 | ≥32 a |
| Ciprofloxacin | 0.12–4 | ≥4 a |
| Daptomycin | 0.25–16 | ≥8 a |
| Erythromycin | 0.25–8 | ≥8 a |
| Gentamicin | 128–1024 | ≥512 b |
| Kanamycin | 128–1024 | ≥1024 b |
| Lincomycin | 1–8 | ≥8 b |
| Linezolid | 0.5–8 | ≥8 a |
| Nitrofurantoin | 2–64 | >64 a |
| Penicillin | 0.25–16 | ≥16 a |
| Streptomycin | 512–2048 | ≥1024 b |
| Quinupristin/Dalfopristin | 0.5–32 | ≥4 a |
| Tetracycline | 1–32 | ≥6 a |
| Tigecycline | 0.015–0.5 c | ≥0.5 b |
| Tylosine tartarte | 0.25–32 | ≥32 b |
| Vancomycin | 0.25–32 | ≥32 a |
a Breakpoint established by the Clinical and Laboratory Standards Institute; b breakpoint established by the National Antimicrobial Resistance Monitoring System; c only a breakpoint for susceptibility has been established [28].
Antimicrobial (n = 16) minimum inhibitory concentration (MIC) distribution data obtained for 104 Enterococcus spp. isolated from 150 rectal faecal samples at feedlot entry (n = 104). The vertical line within each MIC distribution indicates the resistance breakpoint (see Table 1) for each antimicrobial except for tigecycline, where it indicates the susceptible breakpoint.
| Antimicrobial Class | Antimicrobial Agent | Resistance (95% CI) | Percentage of Isolates Yielding Each MIC Value (µg/mL) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | 1024 | |||
| Aminoglycosides | Gentamycin | 0.0 (0.00–3.56) | 100.0 | ||||||||||||||||
| Kanamycin | 0.0 (0.00–3.56) | 98.1 | 1.0 | 1.0 | |||||||||||||||
| Streptomycin | 0.0 (0.00–3.56) | 100.0 | |||||||||||||||||
| Beta-lactam | Penicillin | 0.0 (0.00–3.56) | 23.1 | 20.2 | 31.7 | 21.2 | 3.9 | ||||||||||||
| Fluoroquinolones | Ciprofloxacin | 6.7 (3.24–13.45) | 2.9 | 76.9 | 10.6 | 2.9 | 6.7 | ||||||||||||
| Glycopeptides | Vancomycin | 0.0 (0.00–3.56) | 1.0 | 50 | 48.1 | 1.0 | |||||||||||||
| Glycylcyclines | Tigecycline | 4.8 (2.02–11.03) | 14.4 | 43.3 | 29.8 | 7.7 | 4.8 | ||||||||||||
| Lincosamide | Lincomycin | 60.6 (50.91–69.48) | 36.5 | 1.0 | 1.9 | 5.8 | 54.8 | ||||||||||||
| Lipopeptides | Daptomycin | 25.0 (17.62–34.19) | 1.0 | 4.8 | 19.2 | 50.0 | 23.1 | 1.9 | |||||||||||
| Macrolides | Erythromycin | 1.0 (0.14–6.51) | 90.4 | 2.9 | 1.0 | 3.9 | 1.0 | 1.0 | |||||||||||
| Tylosine tartrate | 1.0 (0.14–6.51) | 1.0 | 3.9 | 24.0 | 57.7 | 11.5 | 1.0 | 1.0 | |||||||||||
| Nitrofurantoins | Nitrofurantoin | 8.65 (4.56–15.80) | 2.9 | 40.4 | 48.1 | 8.7 | |||||||||||||
| Oxazolidinones | Linezolid | 0.0 (0.00–3.56) | 1.0 | 3.9 | 94.2 | 1.0 | |||||||||||||
| Phenicols | Chloramphenicol | 0.0 (0.00–3.56) | 1.0 | 92.3 | 6.7 | ||||||||||||||
| Streptogramins | Quinupristin/dalfopristin | 2.9 (0.93–8.56) | 38.5 | 17.3 | 41.4 | 1.9 | 1.0 | ||||||||||||
| Tetracycline | Tetracycline | 3.9 (1.45–9.80) | 96.2 | 1.0 | 2.9 | ||||||||||||||
Antimicrobial (n = 16) minimum inhibitory concentration (MIC) distribution data obtained for 144 Enterococcus spp. isolated from 150 rectal faecal samples obtained at feedlot exit. The vertical line within each MIC distribution indicates the resistance breakpoint (see Table 1) for each antimicrobial except for tigecycline, where it indicates the susceptible breakpoint.
| Antimicrobial Class | Antimicrobial Agent | Resistance (95% CI) | Percentage of Isolates Yielding Each MIC Value (µg/mL) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | 1024 | |||
| Aminoglycosides | Gentamycin | 0.0 (0.00–2.60) | 100.0 | ||||||||||||||||
| Kanamycin | 0.7 (0.10–4.76) | 70.1 | 25.7 | 3.5 | 0.7 | ||||||||||||||
| Streptomycin | 0.7 (0.10–4.76) | 99.3 | 0.7 | ||||||||||||||||
| Beta-lactam | Penicillin | 0.0 (0.00–2.60) | 8.3 | 12.5 | 11.1 | 23.6 | 43.8 | 0.7 | |||||||||||
| Fluoroquinolones | Ciprofloxacin | 7.6 (4.28–13.27) | 1.4 | 13.2 | 38.2 | 39.6 | 7.6 | ||||||||||||
| Glycopeptides | Vancomycin | 0.0 (0.00–2.60) | 60.4 | 34.0 | 4.2 | 1.4 | |||||||||||||
| Glycylcyclines | Tigecycline | 1.4 (0.35–5.38) | 0.7 | 3.5 | 52.1 | 38.2 | 4.2 | 1.4 | |||||||||||
| Lincosamide | Lincomycin | 84.0 (77.11–89.15) | 13.2 | 2.8 | 1.4 | 82.6 | |||||||||||||
| Lipopeptides | Daptomycin | 22.9 (16.77–30.48) | 1.4 | 12.5 | 63.2 | 22.2 | 0.7 | ||||||||||||
| Macrolides | Erythromycin | 4.2 (1.88–8.96) | 60.4 | 1.4 | 3.5 | 22.2 | 8.3 | 1.4 | 2.8 | ||||||||||
| Tylosine tartrate | 3.5 (1.45–8.07) | 0.7 | 25.7 | 24.3 | 45.8 | 3.5 | |||||||||||||
| Nitrofurantoins | Nitrofurantoin | 53.5 (45.30–61.46) | 3.5 | 43.1 | 53.5 | ||||||||||||||
| Oxazolidinones | Linezolid | 0.0 (0.00–2.60) | 0.7 | 97.2 | 2.1 | ||||||||||||||
| Phenicols | Chloramphenicol | 0.0 (0.00–2.60) | 10.4 | 89.6 | |||||||||||||||
| Streptogramins | Quinupristin/dalfopristin | 18.1 (12.59–25.20) | 13.2 | 4.2 | 64.6 | 17.4 | 0.7 | ||||||||||||
| Tetracycline | Tetracycline | 6.9 (3.78–12.43) | 93.1 | 0.7 | 6.3 | ||||||||||||||
Antimicrobial resistance profiles identified among Enterococcus spp. isolated from rectal faecal samples obtained at entry and exit from an Australian feedlot.
| Antimicrobial Classes | Total No. of Isolates (%) | Resistance Pattern (No. of Isolates) | ||
|---|---|---|---|---|
| Entry (104) | Exit (144) | Entry | Exit | |
| All susceptible | 26 (25.00) | 4 (2.78) | 26 | 4 |
| 1 | 50 (48.08) | 44 (30.56) | LIN (38) | LIN (38) |
| DAP (6) | NIT (6) | |||
| CIP (3) | ||||
| TGC (2) | ||||
| TET (1) | ||||
| 2 | 18 (17.31) | 55 (38.19) | DAP-LIN (11) | LIN-NIT (28) |
| CIP-NIT (1) | LIN-Q/D (9) | |||
| CIP-TET (1) | CIP-LIN (1) | |||
| DAP-NIT (1) | DAP-NIT (7) | |||
| LIN-TIG (3) | DAP-LIN (7) | |||
| LIN-Q/D (1) | CIP-NIT (1) | |||
| LIN-TET (1) | ||||
| ERY-LIN-TYL (1) | ||||
| 3 | 8 (7.69) | 31 (21.53) | DAP-LIN-NIT (6) | LIN-NIT-Q/D (10) |
| CIP-LIN-NIT (1) | CIP-LIN-NIT (3) | |||
| DAP-LIN-TET (1) | CIP-DAP-NIT (3) | |||
| CIP-NIT-TIG (1) | ||||
| DAP-LIN-TET (2) | ||||
| DAP-LIN-Q/D (1) | ||||
| DAP-LIN-NIT (8) | ||||
| NIT-STR-TET (1) | ||||
| LIN-NIT-TET (1) | ||||
| ERY-LIN-TIG-TYL (1) | ||||
| 4 | 2 (1.92) | 9 (6.25) | CIP-DAP-LIN-Q/D (1) | DAP-LIN-NIT-TET (1) |
| ERY-LIN-Q/D-TET-TYL (1) | KAN-LIN-NIT-Q/D (2) | |||
| DAP-ERY-LIN-NIT (1) | ||||
| CIP-DAP-LIN-NIT (1) | ||||
| LIN-NIT-Q/D-TET (1) | ||||
| ERY-LIN-Q/D-TET-TYL (2) | ||||
| ERY-LIN-NIT-TET-TYL (1) | ||||
| 5 | 1 (0.69) | CIP-DAP-LIN-NIT-Q/D (1) | ||
| Non-MDR | 68 (65.4) | 99 (68.8) | ||
| MDR | 11 (10.6) | 41 (28.5) | ||
| Resistance | 79 (76.0) | 140 (96.3) | ||
CIP, Ciprofloxacin; DAP, Daptomycin; ERY, Erythromycin; KAN, Kanamycin; LIN, Lincomycin; NIT, Nitrofurantoin; Q/D, Quinupristin/dalfopristin; STR, Streptomycin; TET, Tetracycline; TIG, Tigecycline; TYL, Tylosine tartrate.
Figure 1Prevalence of resistance to 16 antimicrobials observed among Enterococcus faecium and Enterococcus hirae isolated from faecal samples obtained at entry to (9 E. faecium; 90 E. hirae) and exit from (117 E. faecium; 25 E. hirae) an Australian feedlot.
Figure 2Frequency of Enterococcus faecium and Enterococcus hirae isolates from feedlot cattle faecal samples at entry and exit to the feedlot.
The frequency of antimicrobial resistance genes found in 62 E. faecium isolates selected for whole genome sequencing.
| Antimicrobial Class | Resistance Phenotype | Resistance Gene | Number of Isolates ( |
|---|---|---|---|
| Aminoglycosides | GEN |
| 59 (95.2) |
| Aminoglycosides | AMK |
| 2 (3.2) |
| Aminoglycosides | STR |
| 1 (1.6) |
| β-lactam | AMP |
| 29 (46.8) |
| LsaP (lincosamides, streptogramin As and pleuromutilins) | Q/D, LIN |
| 47 (75.8) |
| Lincosamide | LIN |
| 2 (3.2) |
| Streptogramin | VIR, Q/D |
| 1 (1.6) |
| Macrolide, streptogramin | ERY, Q/D, VIR |
| 59 (95.2) |
| MLS (macrolide, lincosamide, streptogramin) | ERY, LIN, Q/D |
| 3 (4.8) |
| Macrolides, fluoroquinolones | CIP |
| 21 (33.9) |
| Tetracyclines | TET |
| 3 (4.8) |
| Tetracyclines | TET |
| 2(3.2) |
| Tetracyclines | TET |
| 2(3.2) |
| Tetracyclines | TET |
| 2(3.2) |
Agreement between phenotypic and genotypic resistance among the 62 E. faecium isolates subjected to whole genome sequencing.
| Antimicrobial Class | AMR Isolates (%) | Resistance Gene Observed (%) | Agreement (%) |
|---|---|---|---|
| Aminoglycosides | Kanamycin ( | 100 | |
| Streptomycin ( | 0 | ||
| Fluoroquinolones | Ciprofloxacin ( | 66.7 | |
| Lipopeptides | Daptomycin ( | 0 | |
| Lincosamide | Lincomycin ( | 97.4 | |
| Macrolides | Erythromycin ( | 100 | |
| Tylosin tartrate ( | 100 | ||
| Nitrofurantoin | Nitrofurantoin ( | 0 | |
| Streptogramins | Quinupristin/dalfopristin ( | 96.3 | |
| Tetracycline | Tetracycline ( | 100 | |